🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Bringing PRRT to first line. NETTER-2 is out in LANCET. Significantly increased median PFS in G2 and G3 GEP-NETs in favor of PRRT plus octreotide vs high dose octreotide. sciencedirect.com/science/articl… Jaume Capdevila Pamela Kunz, MD, FASCO Thor Halfdanarson

Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-PSMA PET/CT and mpMRI: A Single-Center, Prospective, Single-Arm Trial auajournals.org/doi/10.1097/JU… #ProstateCancer #ProstateMRI #MolecularImaging #CancerResearch

The Homunculus for unspecific bone uptake (UBU) seen on PSMA PET imaging, for more details link.springer.com/article/10.100… #prostatecancer #psma #psmapetct

Fluorine-18 PSMA-1007 PET/CT vs Multiparametric MRI for Prostate Cancer Staging 🔵Tumor Stage: 18F-PSMA-1007 PET/CT superior (45% vs 28%) 🔵Dominant Nodule: PET/CT better (94% vs 83%) 🔵Laterality: PET/CT better (64% vs 44%) 🔵ECE: PET/CT better (75% vs 63%) 🔵SVI: Not

Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer rdcu.be/dQg5y Congrats Renu Eapen for leading this work just published in nature Reviews Urology Declan Murphy Lewis Au Nathan Lawrentschuk GU Cast | Urology podcast!

Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and mpMRI jnm.snmjournals.org/content/early/… 👍Very important publication from UCLA group, congratulations🎉 #ProstateCancer #MolecularImaging #CancerResearch

VI-RADS and PDD-TURBT may together redefine @uroweb Guidelines on Second-TURBT indications for intermediate and high risk NMIBCs. #CUTless; #VIRADS; #PDD; #ReTURBT; #mpMRI Francesco, Del Giudice doi.org/10.1111/bju.16…

Longer follow-up from our landmark ProPSMA study just out European Urology Oncology: PSMA nodal status is prognostic! At 3 years 70% of patients without nodal involvement (N0) disease free, vs. only 46% if N1 CT-defined nodal status is not prognostic. Read the details here:

Excited to share our latest publication in Radiology! We validated the use of nacVI-RADS criteria for assessing muscle-invasive bladder cancer (MIBC) response to neoadjuvant therapies. pubs.rsna.org/doi/epdf/10.11…

3) ⚛️UpFrontPSMA: Adding [177Lu]Lu-PSMA-617 before docetaxel significantly improved undetectable PSA rates (41% vs 16%) in high-volume metastatic hormone-sensitive prostate cancer, with no increased toxicity. 💪A promising step forward! Arun Azad The Lancet Oncology Also don't

Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study jnm.snmjournals.org/content/66/1/54 🔵Compared with conventional imaging, addition of PSMA PET leads to M0 downstaging in every third and

One year ago we published the ANZUP #TheraP follow-up... the Appendix contains the answers to many questions I am often asked. Three of my favourite Figures below: 1) Survival in patients who had FDG-discordant or low PSMA-expression and were not randomised vs.

We're thrilled to announce a major milestone in our first-in-human "VIOLET" study of ☢TERBIUM-161 PSMA for prostate cancer! Not only have we seen no dose-limiting toxicities across 6 cycles up to 7.4 GBq in 30 patients treated to date, but we also wrapped up recruitment more

🚨 #EAU25 Guideline update: role of PSMA PET 4 staging patients with int risk GGG3 prostate ca. Big changes from 2002-2005. From NO recommendation for its use to now recc to use it preferentially over CT/bone scan! 👏🏾. European Association of Urology (EAU) we now have developed packed HOT courses in PSMA

... how common is PSMA-negative significant prostate cancer? In the proPSMA study it was 3.3% Hot of the press in JNM: jnm.snmjournals.org/content/early/… Wonderful work from David Chen and team ProsTIC including James Buteau Declan Murphy

From @vedangmurthy @priyamvadamaitre Maneesh Singh et al: SABR clinical trials special issue; PROBE the DIL. Feasibility and safety report of PSMA-PET based focal boost in prostate SBRT. #RedJournal: tinyurl.com/redmurthy

Is there a role for PSMA PET/CT in oligometatastic RCC? Check out our JNM PEDESTAL study on PSMA-guided metastasis-directed therapy from Peter Mac Cancer Centre Shankar Siva Michael Hofman 🧍33 pts & 60 metastases 🛜 93% radiotherapy 📖Median follow-up> 4y ✅Local control: 94%

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

What's the role of Primary Score in #ProstateCancer diagnosis? Michael Hofman Peter Mac Cancer Centre shares insights at #PSMAandBeyond2025! Watch to learn more about this innovative tool > bit.ly/4monaP3 PSMA and Beyond Conference Prostate Cancer Foundation UCLA UC San Francisco

New data from Denmark suggest improved survival with salvage radiotherapy in the PSMA PET/CT era. jnm.snmjournals.org/content/early/… SNMMI 📊The retrospective analysis excludes patients ineligible for RT based on PSMA PET/CT 💡Randomized data is ideal but challenging in 2025 with